Aurinia Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the global immunology market, announces the appointment of Dr. Michael Hayden to its board of directors. Hayden was most recently the president of global R&D and chief scientific officer at Teva.
“Michael’s scientific acumen and clinical development track record is unparalleled in this industry,” says Richard M. Glickman, chief executive officer and chairman of the board of Aurinia. “His skillset rounds out our board with world class research and development experience which will prove extremely valuable as we initiate our new indications and assess strategic growth options for Aurinia.”
Hayden recently received the accreditation of being named one of the 50 Canadians born in the 20th century who have changed the world. He is the co-founder of three biotechnology companies: NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., and Aspreva Pharmaceuticals Corp. Dr. Hayden sits on different boards including Xenon Pharmaceuticals and Lycera. He is the author of over 860 peer-reviewed publications and invited submissions, and has focused his research primarily on genetic diseases – including genetics of diabetes, lipoprotein disorders, Huntington disease, predictive and personalized medicine. Dr. Hayden was inducted into the Canadian Medical Hall of Fame in 2017. He was named one of PharmaVoice’s “100 of the Most Inspiring People” (2015); awarded an Honorary Doctor of Science by the University of Gottingen (2014); the Luminary award by the Personalized Medicine World Conference (2014); and the Diamond Jubilee Medal (2012), on behalf of HRH Queen Elisabeth II, in recognition of his significant contributions and achievements. Dr. Hayden has also been awarded the Order of Canada (2011), and the Order of British Columbia (2010). He was named Canada’s Health Researcher of the Year by CIHR (NIH of Canada) in 2008, and he received the Prix Galien in 2007, which recognizes the outstanding contribution of a researcher to Canadian pharmaceutical research.
“I hope to build upon the success we created as a team at Aspreva in improving the treatment paradigm for lupus nephritis,” says Hayden. “Aurinia’s commitment to addressing the significant unmet medical need in lupus nephritis is highly encouraging for patients, and I look forward to once again working alongside this exceptional management team as we pursue a successful future for the company.”